


What is claimed is:

1. A compound of the formula:

T0320X




PS

wherein R₁ is selected from the group consisting of

hydrogen, halogen, cyano and $\left[\begin{array}{c} \text{O} \\ || \\ -\text{C}-\text{R}_4 \end{array} \right]$ PS ^{T0321X} R₂ is selected from the group consisting of hydrogen and alkyl(C₁-C₃); R₃ is

T0322X



; ^{PS} R₄ is selected from the group consisting of

hydrogen, alkyl(C₁-C₆) and alkoxy(C₁-C₆); R₅ is selected from the group consisting of hydrogen, alkyl(C₁-C₆), alkenyl(C₂-C₆), $\text{CH}_2\text{C}\equiv\text{CH}$, cycloalkyl(C₃-C₆)methyl, CH_2OCH_3 and $\text{CH}_2\text{CH}_2\text{OCH}_3$; and R₆ is selected from the group consisting of alkyl(C₁-C₆), cycloalkyl(C₃-C₆), -O-alkyl(C₁-C₆), -NH-alkyl(C₁-C₃), -N-dialkyl(C₁-C₃), $(\text{CH}_2)_n\text{O-alkyl(C}_1\text{-C}_3\text{)}$, $(\text{CH}_2)_n\text{-NH-alkyl(C}_1\text{-C}_3\text{)}$ and $(\text{CH}_2)_n\text{-N-dialkyl(C}_1\text{-C}_3\text{)}$, where n is an integer 1 to 3 inclusive.

2. A compound according to Claim 1, wherein

^{T0323X} R₁ is cyano or $\left[\begin{array}{c} \text{O} \\ || \\ -\text{C}-\text{R}_4 \end{array} \right]$ PS R₂ is hydrogen; R₄ is alkyl(C₁-C₆), alkenyl(C₂-C₆) or $\text{CH}_2\text{C}\equiv\text{CH}$; and R₆ is alkyl(C₁-C₆), cycloalkyl(C₃-C₆) or -O-alkyl(C₁-C₆).

3. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl] N-ethylpropanamide.

4. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide.

5. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-propylacetamide.

6. The compound according to Claim 2, which is [3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]methyl-carbamic acid, methyl ester.

7. The compound according to Claim 2, which is 7-[3-[(methoxycarbonyl)methylamino]phenyl]pyrazolo-[1,5-a]pyrimidine-3-carboxylic acid, ethyl ester.

8. The compound according to Claim 2, which is [3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]ethylcarbamic acid, methyl ester.

9. The compound according to Claim 2, which is ethyl(3-pyrazolo[1,5-a]pyrimidin-7-ylphenyl)carbamic acid, ethyl ester.

10. The compound according to Claim 2, which is [3-(3-chloropyrazolo[1,5-a]pyrimidin-7-yl)phenyl]ethyl-carbamic acid, ethyl ester.

11. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-2-propenylacetamide.

12. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-2-propynylacetamide.

13. The compound according to Claim 2, which is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide.

14. A method of ameliorating anxiety in a mammal which comprises administering to said mammal an amount of a compound of Claim 1 sufficient to reduce anxiety.


15. A method of treating epilepsy in a mammal which comprises administering to said mammal an anticonvulsive amount of a compound of Claim 1.

16. A method of inducing sedation or hypnosis in a mammal which comprises administering to said mammal an amount of a compound of Claim 1 sufficient to effect sedation or hypnosis.

17. A method of inducing skeletal muscle relaxation in a mammal which comprises administering to said mammal an amount of a compound of Claim 1 sufficient to relax skeletal muscles.


18. A composition of matter in dosage unit form comprising from 2-750 mg of a compound of Claim 1 in association with a pharmaceutically acceptable carrier.

19. A process for producing a compound of the formula:



wherein R₁ is selected from the group consisting of

hydrogen, halogen, cyano and -C(=O)-R_4 ; R₂ is selected from the group consisting of hydrogen and alkyl(C₁-C₃); R₃ is




; R₄ is selected from the group consisting of

hydrogen, alkyl(C₁-C₆) and alkoxy(C₁-C₆); R₅ is selected from the group consisting of hydrogen, alkyl(C₁-C₆), alkenyl(C₂-C₆), $\text{-CH}_2\text{C}\equiv\text{CH}$, cycloalkyl(C₃-C₆)methyl, $\text{-CH}_2\text{OCH}_3$ and $\text{-CH}_2\text{CH}_2\text{OCH}_3$; and R₆ is selected from the group consisting of alkyl(C₁-C₆), cycloalkyl(C₃-C₆), $\text{-O-alkyl(C}_1\text{-C}_6\text{)}$, $\text{-NH-alkyl(C}_1\text{-C}_3\text{)}$, $\text{-N-dialkyl(C}_1\text{-C}_3\text{)}$,

— END —

$-(CH_2)_n-O-alkyl(C_1-C_3)$, $-(CH_2)_n-NH-alkyl(C_1-C_3)$ and $-(CH_2)_n-N-dialkyl(C_1-C_3)$, where n is an integer from 1 to 3 inclusive, which comprises the steps of


(a) reacting a 1-acetylphenyl-3-amide of the formula:




with dimethylformamide, dimethylacetal at reflux, which produces an N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-alkanamide;

(b) reacting the N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]alkanamide with sodium hydride, which produces an anion;

(c) reacting the anion generated with an alkyl halide of the formula R_5-X , wherein X is Br or I, which produces an N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-alkylalkanamide of the formula:



(d) reacting the N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-alkylalkanamide with a 3-aminopyrazole of the formula:



in glacial acetic acid at reflux, which reaction gives the desired products.